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Abstract: Background
DNA-methylation profiles are responsive to environmental stimuli and metabolic shifts.
This makes DNA-methylation a potential biomarker of environmental-related and
lifestyle-driven diseases of adulthood. Therefore we investigated if white blood cells'
(WBCs) DNA-methylation profiles are associated with myocardial infarction (MI)
occurrence.
Whole genome DNA-methylation was investigated by microarray analysis in 292 MI
cases and 292 matched controls from the large prospective Italian EPIC cohort
(EPICOR study). Significant signals (FDR adjusted P<0.05) were replicated by mass
spectrometry in 317 MI cases and 262 controls from the Dutch EPIC cohort (EPIC-NL).
LINE-1 methylation profiles were also evaluated in both groups.
Results
A differentially methylated region (DMR) within the ZBTB12 gene body and LINE-1
hypomethylation were identified in EPICOR MI cases, and replicated in the EPIC-NL
sample (ZBTB12-DMR meta-analysis, effect-size±se=-0.016±0.003, 95%CI=-0.021;-
0.011, P=7.54x10-10; LINE-1 methylation meta-analysis, effect-size±se=-0.161±0.040,
95%CI=-0.239;-0.082, P=6.01x10-5).
Moreover, cases with shorter time to disease had more pronounced ZBTB12-DMR
hypomethylation (meta-analysis, Men: effect-size±se=-0.0059±0.0017,
PTREND=5.0x10-4, Women: effect-size ±se=-0.0053±0.0019, PTREND=6.5x10-3)
and LINE-1 hypomethylation (meta-analysis, Men: effect-size ±se=-0.0010±0.0003,
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
PTREND=1.6x10-3, Women: effect-size ±se=-0.0008±0.0004, PTREND=0.026) than
MI cases with longer time-to-disease.
In the EPIC-NL replication panel, DNA-methylation profiles improved case-control
discrimination and reclassification when compared with traditional MI risk factors only
(Net Reclassification Improvement (95%CI) between 0.23 (0.02-0.43), P=0.034, and
0.89 (0.64-1.14), P <1x10-5).
Conclusions
Our data suggest that specific methylation profiles can be detected in WBCs, in a
preclinical condition, several years before the occurrence of MI, providing an
independent signature of cardiovascular risk. We showed that prediction accuracy can
be improved when DNA-methylation is taken into account together with traditional MI
risk factors, although further confirmation on a larger sample is warranted. Our findings
support the potential use of DNA-methylation patterns in peripheral blood white cells as
promising early biomarkers of MI.
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We agree with the reviewer that MI risk estimate should not be considered for the
EPICOR panel, being it the discovery panel. As such, we removed MI risk estimates
from the main paper and limited MI risk estimate to the EPIC-NL replica panel.
However, the analysis of the EPICOR panel provides a complementary piece of
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estimate should not be considered as such, this progressively modeled analysis can
nevertheless provide information on the dependence/independence of DNA
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ABSTRACT 
 
Background 
DNA-methylation profiles are responsive to environmental stimuli and metabolic shifts. This makes 
DNA-methylation a potential biomarker of environmental-related and lifestyle-driven diseases of 
adulthood. Therefore we investigated if white blood cells’ (WBCs) DNA-methylation profiles are 
associated with myocardial infarction (MI) occurrence. 
Whole genome DNA-methylation was investigated by microarray analysis in 292 MI cases and 292 
matched controls from the large prospective Italian EPIC cohort (EPICOR study). Significant signals 
(FDR adjusted P<0.05) were replicated by mass spectrometry in 317 MI cases and 262 controls from 
the Dutch EPIC cohort (EPIC-NL). LINE-1 methylation profiles were also evaluated in both groups. 
Results 
A differentially methylated region (DMR) within the ZBTB12 gene body and LINE-1 
hypomethylation were identified in EPICOR MI cases, and replicated in the EPIC-NL sample 
(ZBTB12-DMR meta-analysis, effect-size±se=-0.016±0.003, 95%CI=-0.021;-0.011, P=7.54x10-10; 
LINE-1 methylation meta-analysis, effect-size±se=-0.161±0.040, 95%CI=-0.239;-0.082, P=6.01x10-5). 
Moreover, cases with shorter time to disease had more pronounced ZBTB12-DMR hypomethylation 
(meta-analysis, Men: effect-size±se=-0.0059±0.0017, PTREND=5.0x10-4, Women: effect-size ±se=-
0.0053±0.0019, PTREND=6.5x10-3) and LINE-1 hypomethylation (meta-analysis, Men: effect-size 
±se=-0.0010±0.0003, PTREND=1.6x10-3, Women: effect-size ±se=-0.0008±0.0004, PTREND=0.026) than 
MI cases with longer time-to-disease. 
In the EPIC-NL replication panel, DNA-methylation profiles improved case-control discrimination 
and reclassification when compared with traditional MI risk factors only (Net Reclassification 
Improvement (95%CI) between 0.23 (0.02-0.43), P=0.034, and 0.89 (0.64-1.14), P <1x10-5). 
Conclusions 
Our data suggest that specific methylation profiles can be detected in WBCs, in a preclinical condition, 
several years before the occurrence of MI, providing an independent signature of cardiovascular risk. 
We showed that prediction accuracy can be improved when DNA-methylation is taken into account 
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together with traditional MI risk factors, although further confirmation on a larger sample is warranted. 
Our findings support the potential use of DNA-methylation patterns in peripheral blood white cells as 
promising early biomarkers of MI. 
 
 
Keywords: DNA-methylation; myocardial infarction; early biomarkers; association study; risk 
prediction; risk stratification 
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Background 
Cardiovascular diseases (CVDs) are a leading cause of mortality, morbidity and hospitalization in the 
adult population in western countries, and a major challenge for developing countries that follow a 
westernized-lifestyle. Great attention has been given so far to lifestyle related CVDs risk factors, such 
as unhealthy diet, smoking habits, lack of physical activity, whose deleterious effects may be 
prevented through major lifestyle changes or medical treatments. Apart from monogenic disorders 
associated with cardiovascular risk (e.g., hypertrophic cardiomyopathy, familial 
hypercholesterolemia), there is a strong evidence that a family history of cardiovascular disease and 
stroke enhances individual CVD risks in relatives as compared with general population, that points 
out the importance of genetic factors in the etiology of CVDs. 
Recent genome wide association studies (GWASs) reported several potential genetic risk factors for 
CVDs or intermediate disease phenotypes such as type 2 diabetes, obesity and overweight [1], 
hypertension [2], altered lipid profiles [3], underlying the importance of the genetic component. 
However, the contribution of common genetic variants to non-monogenic CVDs is likely to act in 
combination with environmental factors or via epistatic (gene-gene or gene-environment) interactions. 
As gene-environment interactions are thought to be mediated by epigenetic modifications of the 
genome, epigenetic regulation can be rewarded as the boundary between the inherited genomic asset 
and the environment, potentially playing a major role in disease onset and severity [4]: epigenetic 
changes are in fact dynamic, can be modified both during the early in utero development stages and 
across lifetime by environmental factors as well as diseases, and may be reversible reflecting 
environmental changes [5, 6]. DNA-methylation at CpG dinucleotides is an epigenetic mechanism 
mainly involved in gene expression regulation. DNA-methylation patterns across the genome are not 
uniform: genetic regions spanning genes locations have variable DNA-methylation profiles which are 
linked to regulatory functions (e.g. gene promoters methylation/demethylation regulates gene 
expression), and structural functions in shaping local chromatin structures [7, 8]; instead, intergenic 
regions are usually heavily methylated, since about 45% of the mammalian genome consists of 
transposable and viral elements that are silenced by methylation [9]. Methylation levels of the 
repetitive long interspersed nuclear element-1 (LINE-1) are generally considered as a proxy for global 
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DNA methylation, as LINE-1 elements are widely distributed in the genome and usually heavily 
methylated in the majority of normal tissues. LINE-1 hypomethylation has previously been associated 
with ischemic heart disease and stroke [10], and with altered levels of LDL and HDL [11]. 
Altered DNA-methylation profiles have been linked to oxidative stress [12], atherosclerosis [13], 
ageing [14, 15] and a variety of human diseases ranging from neurological and autoimmune disorders 
to cancer [16-18]. In addition to individual constitutive DNA-methylation profiles, that could per se 
be associated with cardiovascular outcomes [19], subtle and progressive DNA-methylation alterations 
mediated by lifestyle and environmental exposures may in fact lead to dysregulation of several 
metabolic pathways during lifetime, and ultimately to cardiovascular damage and disease [20]. 
However, the few reports linking cardiovascular outcomes to DNA-methylation measured in blood 
cells or vascular tissue [21-23] did not provide conclusive evidences of DNA-methylation 
involvement in cardiovascular disease. 
Apart from few reports of single CpG associations with a disease or a phenotype, it is usually the 
cumulative methylation profile of neighboring CpG sites to be more likely associated to a potential 
functional effect of the methylation status, and the search for differentially methylated regions 
(DMRs) able to differentiate groups of subjects with different phenotypes or outcomes of interest is a 
common approach. Along this line, we conducted an epigenome-wide association study (EWAS) to 
identify DMRs and LINE-1 methylation profiles associated to myocardial infarction (MI) risk in the 
cardiovascular section (EPICOR) of the Italian cohort of the European Prospective Investigation into 
Cancer and Nutrition (EPIC) study, and replicated statistically significant findings in an independent 
case-control study nested in the Dutch EPIC cohort (EPIC-NL) with comparable biological samples 
and information. 
Furthermore, we tested whether MI risk prediction accuracy can be improved when DNA-methylation 
profiles, measured at baseline in a pre-clinical condition, are taken into account together with 
traditional MI risk factors. 
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Results 
Descriptive statistics of the sample are reported in Table 1. Statistically significant differences 
between cases and controls were found in smoking habits, body mass index (BMI) and/or waist-to-hip 
ratio (WHR), serum lipid profile, and blood pressure, in both the discovery (EPICOR) and the 
replication (EPIC-NL) studies (Table1). 
After raw methylation data quality controls (QCs), and removal of cross-hybridizing and Single 
Nucleotide Polymorphisms-containing probes, 425,498 CpGs were included into the following 
analyses. 
 
Case-control differential methylation 
In the EPICOR sample, 25,376 regions with correlated methylation levels were identified with the A-
clustering algorithm [24], and subsequently tested for differential methylation between cases and 
controls (see Methods section): the top-ranking 6 differentially methylated regions are reported in 
Table S1 (Additional file 1). However, only the first region reached statistical significance (FDR Q-
value<0.05), i.e. a 15-CpGs cluster within the gene body (exon1) of the “zinc finger and BTB domain 
containing 12” gene (ZBTB12, Gene ID: 221527), that was hypomethylated in cases as compared to 
controls (effect-size±se=-0.019±0.004, 95%CI -0.03;-0.01, P-value=1.94x10-7, Q-value=0.005). To 
check for sex-specific effects of the ZBTB12-DMR, we stratified EPICOR subjects by sex, and found 
the 15-CpGs cluster still significantly hypomethylated in male cases (effect-size±se=-0.023±0.005, 
95%CI -0.03;-0.01, P-value=1.06x10-6) but not in females (effect-size±se=-0.006±0.006, 95%CI -
0.02;0.005, P-value=0.29). Details on single CpGs are reported in Table S2A (Additional file 1). 
The genomic inflation factor for the overall EPICOR sample was lambda=1.023 (men, lambda=1.043; 
women, lambda=1.017, Q-Q plots in Supplementary Figures S1-S3). 
LINE-1 differential methylation was also tested in the EPICOR overall sample by logistic regression 
analysis: MI cases had statistically significant LINE-1 hypomethylation as compared to controls 
(effect-size±se=-0.511±0.147, 95%CI -0.80;-0.22, P-value=5.00x10-4). At a sex-stratified analysis, 
LINE-1 hypomethylation was still statistically significant in men (effect-size±se=-0.520±0.179, 
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95%CI -0.87;-0.17, P-value=0.004) but not in women (effect-size±se=-0.496±0.319, 95%CI -1.12;-
0.13, P-value=0.12). 
Additionally, for ZBTB12-DMR we found a significant sex-methylation interaction (P-value=0.01), 
whilst for LINE-1 we found no evidence of interaction. 
Results were replicated on the EPIC-NL panel, where the methylation profile of the same ZBTB12-
DMR identified in the discovery phase proved consistent with that of the EPICOR discovery sample, 
with a cluster of 22 contiguous CpGs significantly hypomethylated in Dutch MI cases as compared to 
controls (effect-size±se=-0.013±0.004, 95%CI -0.02;-0.005 P-value=5.82x10-4). Details on ZBTB12-
DMR single CpGs for the EPIC-NL study are reported in Table S2B (Additional file 1). 
At a sex stratified analysis, ZBTB12-DMR was hypomethylated both in EPIC-NL men (effect-
size±se=-0.014±0.007, 95%CI -0.03;-0.001, P-value=0.034) and women (effect-size±se=-
0.012±0.004, 95%CI -0.02;-0.004, P-value=0.006), with effect sizes more comparable between men 
and women than in the EPICOR sample. 
In the EPIC-NL panel, LINE-1 mean methylation levels were lower than those of EPICOR, with an 
average methylation of about 0.8 in EPICOR subjects (men, mean±sd=0.844±0.007; women, 
mean±sd=0.843±0.007) and about 0.6 in EPIC-NL subjects (men, mean±sd=0.624±0.029; women, 
mean±sd=0.613±0.023). As seen in the EPICOR panel, we found LINE-1 hypomethylation also in 
Dutch cases as compared to controls, although with a milder effect (effect-size±se=-0.132±0.042, 
95%CI -0.21;-0.05, P-value=0.001). The sex stratified LINE-1 analysis showed in EPIC-NL men an 
effect-size similar to that found in EPICOR (effect-size±se=-0.40±0.085, 95%CI -0.57;-0.23, P-
value=2.22x10-6), while in EPIC-NL women the effect was much lower and statistically non-
significant (effect-size±se=-0.016±0.046, 95%CI -0.11;0.07, P-value=0.73). 
In the Dutch panel we found no evidence of sex-methylation interaction for ZBTB12-DMR, while we 
found a statistically significant interaction for LINE-1. 
The observation of sex-methylation interactions in both the discovery and replica panels, and further 
considerations addressed in the discussion section, suggested to consider men and women separately 
in all the subsequent analyses. 
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To achieve an overall estimate of the effects of ZBTB12-DMR and LINE-1 methylation across the 2 
subjects panels, we performed a meta-analysis of the EPICOR and EPIC-NL studies. 
The estimated ZBTB12-DMR effect was effect-size±se=-0.016±0.003 in the overall sample 
(P=7.54x10-10, 95%CI=-0.021;-0.011, Cochran’s Q=0.005, d.f.=1, PHET=0.83), effect-size±se=-
0.020±0.004 in men (P=1.82x10-7, 95%CI=-0.027;-0.012, Cochran’s Q=0.007, d.f.=1, PHET =0.79), 
and effect-size±se=-0.010±0.003 in women (P=0.005, 95%CI=-0.017;-0.003, Cochran’s Q=0.004, 
d.f.=1, PHET =0.84). 
The estimated LINE-1 effect was effect-size±se=-0.161±0.040 in the overall sample (P=6.01x10-5, 
95%CI=-0.239;-0.082, Cochran’s Q=0.85, d.f.=1, PHET =0.35), effect-size±se=-0.422±0.076 in men 
(P=3.42x10-8, 95%CI=-0.572;-0.272, Cochran’s Q=0.06, d.f.=1, PHET =0.81), and effect-size±se=-
0.025±0.046 in women (P=0.576, 95%CI=-0.115;0.064, Cochran’s Q=0.70, d.f.=1, PHET =0.40). 
 
DNA-methylation and MI risk 
The MI risk associated to ZBTB12-DMR and LINE-1 hypomethylation was estimated in the EPIC-NL 
replica panel: Recursively Partitioned Mixture Model (RPMM) classes and LINE-1 class (as defined 
in the methods section) were tested for association with MI under different models, from unadjusted 
to fully adjusted. 
When comparing the ZBTB12-DMR lowest methylation class (RPMM3) with the highest methylation 
class (RPMM0), we found MI risk to be significantly associated with hypomethylation in the EPIC-
NL women (fully adjusted, OR=2.75, 95%CI 1.39–5.45, P=0.004), whilst in EPIC-NL men the 
association was statistically non-significant (fully adjusted, OR=2.60, 95%CI 0.79–8.56, P=0.116), 
although direction and effect size were similar. 
We also found a higher MI risk associated with LINE-1 lower methylation class in EPIC-NL men 
(fully adjusted, OR=1.95, 95%CI 1.02-3.71, P=0.043, ref. group above the median). No difference 
was found in EPIC-NL women (fully adjusted, OR=1.05, 95%CI 0.65–1.67, P=0.850) (Additional file 
1, Table S3A). 
The same analysis was performed on the EPICOR discovery sample: even though in this case the ORs 
cannot be considered as indicative of a true estimate of risk being EPICOR subjects the discovery 
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panel, the analysis was nevertheless done to assess whether the progressive inclusion in the model of 
additional variables, namely traditional risk factors (TRFs), could modify the estimate of risk or, on 
the contrary, if DNA methylation may independently contribute to MI risk. No significant evidence of 
inflation/deflation of the DNA-methylation-related MI risk estimate was found nor for the EPIC-NL 
panel nor for the EPICOR panel when progressively adding traditional risk factors (TRFs) as 
covariates in the model (Additional file 1: Tables S3A and B). 
 
Discrimination, reclassification, and calibration on EPIC-NL samples 
We assumed 2 models, including respectively: (1) TRFs only; (2) TRFs plus the ZBTB12-based 
RPMM classes and LINE-1 methylation class. According to the Net Reclassification Improvement 
(NRI) and Integrated Discrimination Improvement (IDI) indices (Table 2), a statistically significant 
improvement in prediction performance was achieved when adding the DNA-methylation profiles to 
the set of baseline predictors (i.e., TRFs), both for EPIC-NL males and females groups. Furthermore, 
we found an improvement in discrimination (Table 2, DeLong's test) comparing the area under 
Receiver Operating Curves (AUC) of the 2 models (Table 2 and Figure 1), although it was not 
statistically significant. 
The calibration plots confirmed the goodness of fit of both the TRFs only and TRFs+Methylation 
models (Figure 2, Hosmer-Lemeshow test), with a better performance of the second one. 
 
DNA-methylation and Time to Disease (TTD) 
The trend test on EPICOR and EPIC-NL subjects, stratified by study and by sex, highlighted a more 
pronounced ZBTB12-DMR hypomethylation in cases with shorter time to disease (EPICOR and 
EPIC-NL meta-analysis, Men: PTREND=0.0005, Women PTREND=0.0065, Table 3). Similarly, LINE-1 
was hypomethylated in cases with shorter time to disease (meta-analysis, Men: PTREND=0.0016, 
Women PTREND=0.026, Table 3). 
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At a post-hoc power analysis, our study was well powered (86% and 82% for males and females 
groups, respectively) to identify DMRs with effect sizes equal to half of the standard deviation, 
considering alpha equal to the False Discovery Rate (FDR) threshold of significance (Q=0.05). 
 
Discussion 
In this study we investigated whether WBCs DNA-methylation profiles may be associated with 
myocardial infarction risk. We examined clusters of adjacent CpG sites with correlated methylation 
levels under the assumption that they could be more reliable indicators of the underlying biological 
function than the single CpG methylation measurement. As we found evidences of sex-methylation 
interactions in both the analyzed panels, in our study the analyses were stratified by sex, in order to 
account for sex-related differences in DNA methylation profiles of genomic regions, of which 
“genomic imprinting” is a well-known example, and to account for sex specific cardiovascular risks. 
For coronary heart disease, sex differences in incidence, disease manifestations, and mortality are well 
recognized [25], and men and women seem not to share the same cardiovascular risk factors [26-29]. 
Moreover, patterns of sex-specific methylation have been reported in literature, and there is a general 
consensus on the occurrence of sex-biased autosomal DNA methylation in specific genes and regions, 
although with contrasting results [30-32]. Sex-associated differential DNA methylation in autosomal 
loci has been reported in genes associated to traits/diseases with different incidence rates according to 
sex [33], as well as in hormone-related genes, suggesting a differential regulation, potentially exerted 
via methylation [31]. Differential DNA-methylation may account for the differences in metabolic 
profiles of men and women, possibly leading to the different incidence, prevalence, symptoms, ages at 
onset and severity of cardiovascular diseases reported in literature. 
In the EPICOR discovery panel, we identified a 15-CpGs cluster within the ZBTB12 gene that was 
significantly differentially methylated in Italian MI cases and controls, and that was also significantly 
hypomethylated in MI cases in the independent Dutch panel. Moreover, ZBTB12-DMR showed a 
trend towards more pronounced hypomethylation in subjects with a short TTD both in the Italian and 
in the Dutch sample. 
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ZBTB12-DMR spans a ~250bp region in ZBTB12 exon 1: although the role of gene-body methylation 
in transcriptional regulation is not fully understood, yet there are evidences of a role of the first exon’s 
DNA-methylation in transcriptional silencing and, putatively, in alternative splicing [34]. All of our 
samples belong to the EPIC cohort, for which no biospecimen suitable for transcriptome analyses is 
available to address the relationship between ZBTB12 methylation and gene expression levels. To 
cope with this issue, we explored ZBTB12 DNA-methylation/gene-expression relationship in 
cryopreserved peripheral blood mononuclear cells from ~80 healthy young subjects belonging to 
another ongoing study, for which we already measured methylation and gene-expression levels: in our 
data, ZBTB12 mRNA abundance was below the background level (as assessed by Illumina 
HumanHT12 gene-expression BeadChip), while ZBTB12 methylation levels were comparable to that 
of EPICOR and EPIC-NL controls (data not shown). No relationship was found also with the gene-
expression levels of the nearby genes (data not shown). Data mining in freely available resources (e.g. 
BioGPS, AceView, ProteinAtlas, Genome Atlas) confirmed the generalized low ZBTB12 mRNA level 
in tissues and cell types, although ZBTB12 protein is detectable in many tissues, including 
cardiovascular tissues. Although no clear function is described for ZBTB12, this protein is probably 
involved in transcriptional regulation, like other members of the ZBTB family of methyl-CpG binding 
proteins (MBPs). This is also supported by its mainly nuclear localization. MBPs bind to methylated 
DNA and recruit chromatin remodeling co-repressor complexes, resulting in compaction of chromatin 
into its transcriptionally inactive state [35]. Specifically, members of the ZBTB family function as 
mediators of epigenetically controlled gene silencing by recognizing symmetrically methylated CpG 
sites and sequence specific non methylated sites [8, 35]. 
According to the Human Protein Reference Database [36], ZBTB12 (HPRD ID: 15691) directly 
interacts with Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) and RAP1 GTPase Activating 
Protein1 (RAP1GAP). RAP1GAP down-regulates the activity of Ras -associated protein 1 (RAP1), a 
small GTPase involved in several aspects of cell adhesion, including angiogenesis [37]. HRAS, a 
member of the RAS oncogene family, is a key transducer in several growth-signaling events that may 
trigger cardiovascular complications such as angiogenesis and vascular permeability [38], and may be 
involved in inflammatory proliferative arterial diseases, including atherosclerosis and restenosis after 
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angioplasty [39]. The RAS-MEK-ERK cascade has been described as implicated in cardiac 
hypertrophy and heart failure, and ERK signal transduction pathways were associated with cardiac 
hypertrophy [40]. 
In addition to gene/region specific DNA-methylation, we investigated the cumulative DNA-
methylation profile of LINE-1 repetitive sequences and found LINE-1 hypomethylation in MI cases, 
statistically significant in men in both panels, but not in women. LINE-1 hypomethylation was 
associated to cardiovascular-related traits in previous studies [10, 11], and it is associated to MI and 
shorter TTD in the present study. DNA hypomethylation is regarded as a cause of genomic instability, 
and as a matter of fact LINE-1 hypomethylation was found in several conditions, including cancer 
[41], autoimmune diseases [42] and cardiovascular diseases [10]. Specifically, global 
hypomethylation of genomic DNA and gene-specific methylation profiles have been associated to 
conditions already known to predispose to cardiovascular diseases, such as cellular ageing [43], 
atherosclerotic plaques [44], menopausal state and osteoporosis [45]. On the other hand, LINE-1 
hypomethylation could simply be a marker of increased white blood cells proliferation due to 
inflammatory or immunological responses which are known to be active during cardiovascular 
pathogenic processes [10]. In vitro experiments on mouse embryonic stem cells showed that folate 
deficiency affected the homeostasis of folate-mediated one-carbon metabolism, leading to reduced 
LINE-1 methylation [46]. In a targeted analysis, we recently demonstrated on a subset of the EPICOR 
cohort (206 MI cases and 206 matched controls), an inverse relationship between B-vitamins intake 
and DNA-methylation of genes belonging to One Carbon Metabolism and Homocysteine pathways 
[20]. These previous observations, together with our current finding of LINE-1 hypomethylation in 
cases compared to healthy controls, suggest a link between DNA-methylation patterns and CVD risk 
conferred by low folate and B-vitamins intake, that is worthy of further investigation. 
 
Overall, this study analyzed 609 cases and 554 controls, and was sufficiently powered to detect effects 
of the magnitude we found. The discovery and the replica panels share homogeneous features: both 
belong to the European EPIC cohort, subjects were all enrolled in the nineties, and biosamples were 
collected and stored at enrollment according to shared standard protocols [47]. Nevertheless, a 
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limitation of the study is that while EPICOR cases and controls were matched by age, sex, center and 
season of recruitment, this could not be achieved for the EPIC-NL sample, since a DNA sample 
suitable for methylation analysis was not available for all the subjects enrolled in the Dutch EPIC 
cohort. 
Another limitation is that the assessment of the methylation levels was done with different methods 
for the two panels. However, our approach that considered the regional methylation profile as a whole 
instead of single CpGs may contribute to overcome the bias due to measure errors at single CpGs 
level, as highlighted by the correlation between the methylation measures of 16 control samples 
assayed with both BeadChip and MassArray Assay (Additional file 2: Supplementary Methods). 
Moreover, although the CpGs positions assayed with the 2 methods are not exactly the same due to 
technical constrains (Additional file 2: Supplementary Methods, and Figure S4), still the analysis of 
methylation data collected with each one of the two different techniques highlighted a cluster of CpGs 
with correlated methylation levels within exon1 of ZBTB12, hypomethylated in MI cases vs controls. 
This complies with our study design assumption that the methylation status of multiple CpGs with 
correlated methylation could better describe the cumulative methylation status of the underlying 
region, and that this could be potentially related to the underlying biological function, if any. The 
same goes for LINE-1 methylation, which is defined as the cumulative DNA-methylation status of the 
several CpGs located in LINE-1 sequences across the genome. Also in this case, different portions of 
LINE-1 sequence were investigated with the 2 techniques, i.e. CpGs scattered across the whole LINE-
1 sequence were analyzed on the BeadChip, whereas CpGs within base pairs 335–767 of the LINE-1 
promoter (Gen-Bank accession number X58075.1) were analyzed by MassArray according to Wang 
et al. [48] (Figure S4). 
Despite slight differences between EPICOR and EPIC-NL panels in LINE-1 average methylation 
levels, arguably due to the use of different methods and different assayed CpGs, our results 
highlighted the same effect trend in both the EPIC sub-cohorts. 
When included in the same multivariate models, the estimated risks associated to ZBTB12-DMR and 
LINE-1 methylation profiles were not attenuated by the adjustment for known risk factors (Additional 
file 1: Table S3A and B), suggesting that they independently contribute to MI risk estimate. 
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Moreover, we observed that discrimination between MI cases and controls and prediction accuracy 
both improved when DNA-methylation was taken into account together with traditional risk factors, 
suggesting the DNA-methylation could be an independent predictor of MI risk, although further 
confirmation on a larger sample is warranted. 
Our results highlight the possibility to identify MI-related methylation marks on DNA from blood 
samples drawn in a preclinical condition, for some subjects many years before the MI. Unfortunately, 
due to the initial EPIC study design that envisaged only one blood sampling at enrollment time, it was 
not possible to monitor individual DNA-methylation level changes at different time points. Further 
replication in additional cohorts with prospective design and biospecimens sampled at multiple points 
along time is warranted to elucidate DNA-methylation changes across time, from ‘healthy’ status to 
MI. This will allow a better estimation of the ZBTB12-DMR and LINE1 de-methylation rates 
associated with increased MI risk, in the view of a personalized risk assessment that will take into 
account TRFs and MI risk biomarkers, such as DNA-methylation profiles. 
 
Conclusions 
To the best of our knowledge, this is the first paper reporting an association between MI risk and 
DNA-methylation profiles identified from epigenome-wide data in prospectively collected subjects 
with well-recorded clinical endpoints, and replicated in an independent sample form the same large 
European prospective cohort. 
Taken together, the reported results suggest the possible role of DNA-methylation patterns in 
peripheral blood white cells as promising early MI biomarkers to be potentially used, together with 
TRFs, for individual MI risk assessment. 
 
Methods 
Study population 
For the discovery phase, 292 MI cases and 292 matched healthy controls were recruited among those 
enrolled in the EPICOR study [49], a case-cohort study nested within the EPIC-Italy prospective 
cohort (~50.000 participants) [50]. All EPICOR cases developed MI after recruitment (average time 
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to diagnosis 6.90 years). Cases were identified at cohort follow-up from hospital discharge databases, 
and were then matched with healthy controls from the same cohort without evidence of MI at follow-
up. Matching parameters were age at recruitment (±1.5 years), sex, center and season of recruitment. 
Results from the discovery phase were replicated in an independent sample of 317 Dutch subjects 
from the prospective EPIC-NL cohort [51] who developed MI during follow-up (average time to 
diagnosis 5.64 years) and 262 unmatched healthy controls from the same cohort. Details on 
anthropometrics, lifestyle, biochemical measurements, and MI definition are provided in Additional 
file 2: Supplementary Methods. 
 
Ethical considerations 
Our study complies with the Declaration of Helsinki principles, and conforms to ethical requirements. 
All volunteers signed an informed consent form at enrollment in the respective studies. The EPIC 
study protocol was approved by Ethics Committees of the International Agency for Research on 
Cancer (Lyon, France), as well as by local Ethical Committees of the participant centers. The 
EPICOR study was approved by the Ethical Committee of the Human Genetics Foundation (Turin, 
Italy). For the Dutch EPIC samples, approval was obtained by the Institutional Review Board of the 
University Medical Center Utrecht (Utrecht, the Netherlands) and the Medical Ethical Committee of 
TNO Nutrition and Food Research (Zeist, the Netherlands). 
 
DNA-methylation measurement 
DNA-methylation was measured in DNA from WBCs collected at subject enrollment into EPIC and 
stored in liquid nitrogen [47]. The Infinium HumanMethylation450 BeadChip (Illumina Inc., San 
Diego, CA) and the MALDI-TOF mass spectrometry methylation assay (Sequenom Inc., S. Diego, 
CA, USA) were used for the discovery phase and the replication phase, respectively. Laboratory 
methods for DNA-methylation levels measurement, are detailed in Additional file 2: Supplementary 
Methods. 
 
Whole-genome methylation data quality control (QC) and normalization procedures 
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DNA-methylation levels were measured as Beta-values, ranging from 0 to 1. We excluded from the 
analyses: i) single Beta-values with detection p-value≥0.01; ii) CpG loci with detection p-value≥0.01 
in more than 20% of the assayed samples; iii) probes containing SNPs with MAF≥0.05 in the CEPH 
(Utah residents with ancestry from northern and western Europe, CEU) population; iv) samples with a 
global call rate ≤95%. 
From the 435,457 CpGs that passed QCs (~95% of BeadChip content), we further removed 9,959 
CpGs whose methylation signal was detected by cross-hybridizing and SNPs-containing probes [52]. 
A total of 292 matched case-control pairs and 425,498 CpG sites were used in the following analyses. 
Background normalization was performed on raw methylation data according to Marabita et al. [53]. 
 
Statistical analyses 
Statistical analyses were conducted using the open source R v3.0.1 package [54]. 
Analyses were performed stratifying by sex, in order to account for the occurrence of sex-specific 
DNA-methylation, and for the different cardiovascular risk profiles between men and women (see 
Discussion). Descriptive statistics of sample characteristics, anthropometrics, lipid profiles, 
hypertension, and lifestyle habits (smoke, alcohol consumption) was performed. 
 
Case-control DMRs analysis 
We analyzed the EPICOR methylation data (discovery phase, 425,498 CpGs) with the A-clustering 
algorithm [24] to identify clusters of 2 or more neighboring CpGs with correlated methylation levels. 
The association between each one of the identified methylation clusters and case-control status was 
tested by Generalized Estimating Equations (GEE) [55] to identify DMRs between MI cases and 
controls. We adjusted the analyses for matching variables (age at recruitment, center, season of 
recruitment, sex in the overall analyses), estimated WBC composition (for the EPICOR panel only), 
and for the major cardiovascular risk factors [56] i.e. smoking status, BMI, blood pressure, physical 
activity (for the EPICOR panel only). EPICOR sample analyses were additionally adjusted for 
‘control probes’ Principal Components, while EPIC-NL analyses did not require batch correction (see 
Additional file 2, Removal of technical biases). 
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As fasting glucose measurement was missing for >20% of the EPICOR and EPIC-NL samples, 
glucose level was excluded from the adjustment covariates. Lipid levels were missing for 48 EPICOR 
subjects: lipid levels were omitted as covariates too, after verification that inclusion or exclusion of 
this parameter did not substantially affected the results (Additional File 2: Supplementary Methods). 
Due to the small number of subjects with incident diabetes identified at follow-up (n=9), diabetes was 
not included in the covariate list. 
DMRs with FDR Q-value<0.05 were considered statistically significant and investigated in the EPIC-
NL sample with the same statistical approach. The Q statistic [57] was used to assess heterogeneity 
between the two sample panels: provided no heterogeneity was found, an inverse variance weighted 
fixed effect meta-analysis, was additionally carried out to achieve an overall estimate of the two 
studies. 
 
Case-control LINE-1 methylation analyses 
To analyze LINE-1 methylation levels from BeadChip data we first identified all the BeadChip’s 
CpGs lying in LINE-1 sequences according to the UCSC Genome Browser database. The cumulative 
DNA-methylation level of LINE-1 sequences was computed, for each subject, as the average 
methylation level across the 12,762 CpGs, out of the >450K assayed on the BeadChip, that were 
annotated in LINE-1 sequences. Case-control differences were assayed by logistic regression, with 
methylation levels as a continuous variable, and the same adjustment used for the case-control DMRs 
discovery and replication analyses. For replication purposes, the same analysis was performed on the 
EPIC-NL samples using LINE-1 methylation data from MassARRAY analysis (Additional file 2: 
Supplementary Methods). A LINE-1 methylation meta-analysis of the two studies was also done as 
described above. 
 
DNA methylation and MI risk 
EPICOR and EPIC-NL subjects, stratified by sex and by study, were clustered with a RPMM 
algorithm [58] into 4 classes according to their ZBTB12-DMR methylation profile, irrespective of 
case-control status. Each subject was also allocated to a LINE-1 methylation class (above/below the 
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median). The association between MI and DNA-methylation (as RPMM class, or LINE-1 methylation 
profile) was evaluated on the EPIC-NL panel by logistic regression analysis, stratifying by sex. 
Moreover, to test the dependence/independence of the DNA-methylation effects from the traditional 
risk factors, we compared the ORs associated to each RPMM class and to LINE-1 methylation status 
under three logistic regression models, progressively including additional covariates at each step. To 
this purpose, the same analysis was done on the EPICOR discovery panel as well, under the caveat 
that the estimated ORs in this case should not be considered as a risk estimate, being assessed in the 
discovery panel and, as such, putatively inflated. Briefly, Model 1 included the matching variables 
only, Model 2 included the whole set of covariates used for the case-control DMRs discovery and 
replication analyses, and Model 3 was fully adjusted with the comprehensive set of variables as 
available in the 2 studies. Further methodological details are provided in Additional file 2: 
Supplementary Methods. 
 
Discrimination, reclassification, and calibration 
We tested for the improvement in the performance of MI risk prediction when including DMRs and 
LINE-1 profiles identified in the EPICOR dataset (discovery phase) by running discrimination and 
reclassification analyses on the independent EPIC-NL dataset. Two models were compared: the first 
one included only TRFs that were significantly associated to MI in our study or reported in the 
literature to be associated to MI (Figure 1, legend); the second one comprised TRFs as model 1 plus 
ZBTB12-RPMM classes and LINE-1 methylation class. 
For discrimination, we compared the AUC of the two models by the DeLong test [59]. For 
reclassification, we computed the NRI and IDI indices [60]. The goodness-of-fit was evaluated by the 
Hosmer-Lemeshow (HL) test [61] in order to assess the proper calibration of the model. 
 
DNA-methylation and TTD 
Being EPICOR and EPIC-NL prospective cohorts with incident MI cases identified during cohort 
follow-up, we investigated the relationship between methylation and TTD, i.e. the time lapse between 
blood collection and the MI event. EPICOR and EPIC-NL cases, stratified by study and by sex, were 
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divided in tertiles according to TTD. Control groups were used as reference. The occurrence of a 
linear trend between DNA-methylation levels and TTD, as ordinal categorical variable, was tested by 
GEE (details in Additional file 2). 
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Abbreviations 
WBCs: white blood cells 
MI: myocardial infarction 
DMR: differentially methylated region 
CVD: cardiovascular disease 
LINE-1: long interspersed nuclear element-1 
EWAS: epigenome-wide association study 
EPIC: European Prospective Investigation into Cancer and Nutrition 
BMI: body mass index 
WHR: waist-to-hip ratio 
QC: quality control 
FDR: false discovery rate 
TRFs: traditional risk factors 
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Figure Legends 
 
Figure 1. Receiver Operating Curves (ROC), EPIC-NL validation sample 
Model1 (TRFs, dotted line) includes age, sex, center of recruitment, smoking habits, BMI, WHR, 
lipid levels, blood pressure, menopausal status in women. 
Model2 (TRFs+Meth., solid line), as Model1 plus ZBTB12-RPMM classes, LINE-1 methylation 
profile. 
Panel A: EPIC-NL Men; B: EPIC-NL Women. Statistics in Table 2. 
 
Figure 2. Calibration Plots, EPIC-NL validation sample 
Goodness of Fit, Model1 (TRFs, triangles) vs Model2 (TRFs+Meth., dots). 
Hosmer-Lemeshow test: Men: PTRF=0.118, PTRF+M=0.414; Women: PTRF=0.636, PTRF+M=0.724 
Panel A: EPIC-NL Men; B: EPIC-NL Women. Statistics in Table 2. 
 
Supplementary Figures Legends 
Figure S1: Quantile-Quantile plot, EPICOR overall subjects 
 
Figure S2: Quantile-Quantile plot, EPICOR men 
 
Figure S3: Quantile-Quantile plot, EPICOR women 
 
Figure S4: Locations of ZBTB12 and LINE-1 CpG sites investigated by Sequenom MassARRAY 
CpGs (in red) investigated within ZBTB12-DMR, LINE-1, and flanking primers (upper case: 
complementary to DNA; lower case: T7-promoter sequence and 10mer tag). 
CpG sites that could not be tested individually due to MassArray technology constrains, but had to be 
tested jointly with neighboring CpGs as a single unit, are underlined: the methylation level is the 
cumulative value of all the sites within the CpG unit. 
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TABLE 1. EPICOR and EPIC-NL sample descriptive 
  EPICOR MEN    EPICOR WOMEN    EPIC-NL MEN   EPIC-NL WOMEN    
  
CASES 
(N=188) 
CONTROLS 
(N=188) 
  
 CASES 
(N=104) 
CONTROLS 
(N=104) 
  
 CASES 
(N=116) 
CONTROLS 
(N=83) 
  
CASES 
(N=201) 
CONTROLS 
(N=179) 
  
 
 
N (%) N (%) 
 
 
N (%) N (%) 
 
 
N (%) N (%) 
 
N (%) N (%) 
  
 
Centre                            
Varese 42 (22.34) 42 (22.34)    67 (65.69) 67 (65.69)                 
Ragusa 19 (10.11) 19 (10.11)    3 (2.94) 3 (2.94)                 
Turin 127 (67.55) 127 (67.55)    23 (22.55) 23 (22.55)                 
Naples -- --    11 (10.78) 11 (10.78)                 
Utrecht               -- --   149 (74.13) 140 (78.21)    
Bilthoven               116 (100) 83 (100)   52 (25.87) 39 (21.79)    
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Smoking status 
      
 
    
 
 
            
 
Never 33 (17.55) 50 (26.60)    53 (50.96) 73 (70.19)    19 (16.38) 18 (21.69)   60 (29.85) 85 (47.49)    
Former 70 (37.23) 87 (46.28) 
 
* 11 (10.58) 13 (12.50) 
 
* 34 (29.31) 32 (38.55)   48 (23.88) 48 (26.81)   * 
Current 85 (45.21) 51 (27.13)    40 (38.46) 18 (17.31)    62 (53.45) 33 (39.76)   89 (44.28) 45 (25.14)    
NA         1 (0.86)   4 (1.99) 1 (0.56)   
Menopausal Status 
      
 
      
 
            
 
Pre-menopause        27 (25.96) 26 (25.00)          43 (21.39) 42 (23.46)    
Post-menopause        77 (74.04) 78 (75.00)          158 (78.61) 137 (76.54)    
  Mean±SD Mean±SD    Mean±SD Mean±SD    Mean±SD Mean±SD   Mean±SD Mean±SD   
Age at recruitment (years) 50.98±6.93 50.92±7.01    55.01±7.40 55.01±7.51    51.51±7.68 51.11±8.30   58.56±8.74 59.30±8.12    
Avg. Follow -up (years) 12.98±2.29 13.26±2.06     12.24±1.97 12.66±1.16    13.07±5.21 15.25±2.31†  
 
11.61±4.92 14.27±2.62† 
 
 
Avg. TTD (years) 7.14±3.88  --    6.54±3.57 --    5.44±3.22 -- 
 
5.76±3.06 --    
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BMI (kg/m2) 27.05±2.96 26.35±3.12† 
 
 26.95±4.69 25.93±5.11    27.12±3.30 27.08±3.15   26.47±4.24 26.05±4.17    
WHR 0.94±0.06 0.93±0.06† 
 
 0.83±0.06 0.79±0.06† 
 
 0.95±0.08 0.94±0.08   0.82±0.07 0.80±0.07†   
Total Cholesterol (mmol/L) 6.10±1.12 5.86±1.22    6.42±1.23 6.36±1.16    6.24±0.95 5.79±0.97† 
 
5.51±0.98 5.27±0.98† 
 
 
LDL Cholesterol (mmol/L) 3.94±1.00 3.60±1.01† 
 
 4.07±1.15 3.97±1.01    3.60±0.94 3.34±0.92   3.44±0.82 3.19±0.77† 
 
 
HDL Cholesterol (mmol/L) 1.30±0.29 1.48±0.37†   1.55±0.39 1.76±0.41† 
 
 1.11±0.28 1.12±0.28   1.16±0.33 1.27±0.36† 
 
 
Triglycerides (mmol/L) 1.89±0.99 1.71±1.04    1.74±1.43 1.38±0.57†   2.28±1.27 2.28±1.46   1.77±0.98 1.54±0.91†   
SBP (mmHg) 137.47±16.56 135.04±19.03    144.36±9.77 136.76±10.08† 
 
 134.43±17.61 128.51±14.93†  138.50±22.23 133.59±20.76† 
 
 
DBP (mmHg) 85.38±8.96 84.97±10.80    86.08±22.13 84.97±19.02    84.96±10.71 80.60±10.19† 
 
81.99±11.20 79.22±11.18† 
 
 
Alcohol (gr/day) 23.46±20.26 24.98±20.90    6.29±10.78 8.76±15.43    19.42±21.89 18.41±22.27   7.55±11.24 8.44±12.21    
 
*Chi-Squared test P<0.05 
†T-Test P<0.05 
LDL = Low Density Lipoprotein; HDL = High Density Lipoprotein; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure; TTD: time to disease.  
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TABLE 2. Discrimination and reclassification indices, EPIC-NL validation sample 
 
 
 
 
 
 
 
 
 
  
AUCTRF (95%CI) AUCTRF+M (95%CI) DeLong's test P NRI (95%CI) PNRI IDI (95%CI) PIDI 
EPIC-NL MEN 0.66 (0.58-0.74) 0.70 (0.63-0.78) 0.147 0.47 (0.19-0.76) 0.001 0.04 (0.01-0.08) 0.004 
EPIC-NL 
WOMEN 0.66 (0.61-0.72) 0.69 (0.63-0.74) 0.095 0.23 (0.02-0.43) 0.034 0.03 (0.01-0.05) 0.001 
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Table 3. DNA-methylation and time-to-disease (TTD) 
 
  ZBTB12  
 
   LINE-1  
  
 
TTD Class* Range
‡ 
Effect-
size 
95%CI se PTREND Cochran’s Q  
Effect-
size
95%CI se PTREND Cochran’s Q 
EPICOR MEN 
 
          
TTD class1 8.89-14.66            
TTD class2 5.23-8.88 -0.0054 -0.0090;-0.0018 0.0018 0.0036   -0.0009 -0.0016;-0.0003 0.0003 0.0044  
TTD class3 0.26-5.20 
 
          
EPIC-NL MEN            
TTD class1 6.97-12.31 
 
          
TTD class2 3.53-6.86 -0.0093 -0.0182;-0.0005 0.0045 0.0389   -0.0035 -0.0070;0.00003 0.0018 0.0537  
TTD class3 0.23-3.52 
 
          
Meta-analysis -0.0059 -0.0093;-0.0027 0.0017 0.0005 0.65†  -0.0010 -0.0017;-0.0004 0.0003 0.0016 2.03† 
EPICOR WOMEN 
 
          
TTD class1 8.16-14.02            
TTD class2 4.40-8.06 -0.0056 -0.0106;-0.0007 0.0025 0.0250   -0.0008 -0.0017;0.00004 0.0004 0.0636  
TTD class3 0.33-4.30 
 
          
EPIC-NL WOMEN            
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TTD class1 7.35-12.30 
 
          
TTD class2 4.40-7.21 -0.0047 -0.0106;0.0011 0.0030 0.1147   -0.0011 -0.0032;0.0010 0.0011 0.2970  
TTD class3 0.04-4.38 
 
          
Meta-analysis -0.0053 -0.0091;-0.0015 0.0019 0.0065 0.05†  -0.0008 -0.0016;-0.0001 0.0004 0.0263 0.07† 
 
*Healthy controls (TTD class 0) were used as reference group. Cases were divided in tertiles (TTD classes 1 to 3) 
‡Minimum and maximum TTD (i.e. time-lapse in years from enrollment to occurrence of MI) for each class 
†d.f.=1, P=ns 
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